期刊文献+

人FGF-21基因的克隆、表达及其调节脂肪细胞糖代谢的活性 被引量:6

Cloning, expression and glucose regulation activity of human FGF-21
下载PDF
导出
摘要 成纤维细胞生长因子FGF-21是FGF家族的一个新成员,最近的研究发现其具有调节血糖的作用,有望成为治疗2型糖尿病的基因药物。文章应用RT-PCR技术,从成人肝脏中克隆人源的FGF-21成熟蛋白基因,并将其克隆到T载体上,经测序鉴定后,将其亚克隆到原核表达载体pSUMO上,转入大肠杆菌Rosetta(DE3)中。鉴定阳性克隆后,用IPTG诱导FGF-21表达,并用Ni-NTA柱进行亲和层析纯化。以3T3-L1脂肪细胞的葡萄糖吸收实验来鉴定FGF-21表达产物促进糖吸收的活性。结果表明,FGF-21成熟蛋白基因大小为546bp,测序结果与GenBank数据库中的序列一致。SDS-PAGE与Western blotting结果表明:人源FGF-21成熟蛋白大小19.4kDa,经3T3-L1脂肪细胞的葡萄糖吸收实验验证其具有促进葡萄糖吸收的生物活性,并且GLUT1是FGF-21发挥生物学作用的终末执行单位。 Fibroblast growth factor (FGF)-21 is a recently discovered glucose regulator and has potential to become therapeutics for treatment of type 2 diabetes. The aim of this study was to clone and express human FGF-21 gene and characterize its bioactivity for glucose regulation. The hFGF-21 cDNA was cloned from human liver by RT-PCR and subcloned into the pSUMO vector after sequencing confirmation. The recombinant plasmid was transformed into Escherichia coli Rosetta strain. The FGF-21 protein expression was induced by IPTG and purified by Ni-NTA agarose. The FGF-21 product was verified by Western blotting analysis with specific antibody. The bioactivity of the purified protein was examined by glucose uptake assay in 3T3-L1 adipocytes. The cloned hFGF-21 gene consisted of 546 bp, which was in agreement with the published data in GenBank. SDS-PAGE analysis showed that hFGF-21 expressed in the E. coli system was 19.4 kDa in size. The glucose uptake assay in 3T3-L1 adipocytes indicated that the purified hFGF-21 could stimulate glucose uptake in a dose-dependent manner, and glucose transporters (GLUT1) is the functional unit.
出处 《遗传》 CAS CSCD 北大核心 2010年第6期583-587,共5页 Hereditas(Beijing)
基金 黑龙江省科技厅重点攻关项目(编号:2006G0461-00) 黑龙江省博士后科研启动资助金 黑龙江省教育厅项目(编号:11521022) 哈尔滨市科技创新人才研究专项资金(编号:2008RFQXS017)项目
关键词 人源FGF-21 成熟蛋白 糖尿病 小泛素相关修饰蛋白表达载体 human FGF-21 mature protein diabetes mellitus SUMO
  • 相关文献

参考文献21

  • 1文世林.糖尿病流行的全球趋势和国内现状[J].河南诊断与治疗杂志,2002,16(1):14-15. 被引量:18
  • 2李延兵,翁建平,许雯,陈小华,廖志红,姚斌,邓婉萍,欧香忠,胡国亮.短期持续胰岛素输注治疗对初诊2型糖尿病患者胰岛β细胞功能的影响[J].中国糖尿病杂志,2003,11(1):10-15. 被引量:777
  • 3Nishimura T,Nakatake Y,Konishi M,Itoh N.Identification of a novel FGF,FGF-21,preferentially expressed in the liver.Biochim Biophys Acta,2000,1492(1):203-206.
  • 4Kharitonenkov A,Shiyanova TL,Koester A,Ford AM,Micanovic R,Galbreath EJ,Sandusky GE,Hammond LJ,Moyers JS,Owens RA,Gromada J,Brozinick JT,Hawkins ED,Wroblewski VJ,De-Shan Li,Mehrbod F,Jaskunas SR,Shanafelt AB.FGF-21 as a novel metabolic regulator.J Clin Invest,2005,115(6):1627-1635.
  • 5Ausubel FM,Brent R,Kingston RE,Moore DD,Seidman JG,SmithJ A,Strum K.Short Protocols in Molecular Biology,3rd ed.Boston:John Wiley&Sons,Inc,1992,652-658.
  • 6Sambrook J,Fritsch EF,Manutus T.Mogecular Cloning,ALaboratory Manual,2nd ed.New York:Cold Spring Harbor Laboratory Press,1989,9880-9898.
  • 7姜媛媛,刘铭瑶,任桂萍,王文飞,刘晓民,李德山.鼠源成纤维细胞生长因子-21对脂肪细胞糖代谢的作用[J].生物化学与生物物理进展,2009,36(2):157-164. 被引量:18
  • 8Butt TR,Edavettal SC,Hall JP,Mattern MR.SUMO fusion technology for difficult-to-express proteins.Protein Expr Purif,2005,43(1):1-9.
  • 9Zuo X,Li S,Hall J,Mattern MR,Tran H,Shoo J,Tan R,Weiss SR,Butt TR.Enhanced expression and purification of membrane proteins by SUMO fusion in Escherichia coli.Struct Funct Gen,2005,6(2-3):103-111.
  • 10Zhao FQ,Keating AF.Functional properties and genomics of glucose transporters.Curr Genomics,2007,8(2):113-128.

二级参考文献35

  • 1Uusitupa M I, Niskanen L K, Siitonen O, et al. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipo-protein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia, 1993, 36 (11): 1175-1184
  • 2Clark C M Jr. How should we respond to the worldwide diabetes epidemic. Diabetes Care, 1998, 21(4): 475-476
  • 3Aiello L P, Gardner T W, King G L, et al. Diabetic retinopathy. Diabetes Care, 1998, 21(1): 143-156
  • 4Mooradian A D. Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Drugs, 1996, 51(6): 931 -941
  • 5Scheen A J. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments. Drugs, 1997, 54(3): 355-368
  • 6Wente W, Efanov A M, Brenner M, et al. Fibroblast growth factor-21 improves pancreatic-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and akt signaling pathways. Diabetes, 2006, 55(9): 2470-2478
  • 7Kharitonenkov A, Wroblewski V J, Koester A, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology, 2007, 148(2): 774-781
  • 8Kharitonenkov A, Shiyanova T L, Koester A, et al. FGF-21 as a novel metabolic regulator. J Clin Invest, 2005, 115(6): 1627-1635
  • 9Marblestone J G, Edavettal S C, Lim Y, et al. Comparison of SUMO fusion technology with traditional gene fusion systems: Enhanced expression and solubility with SUMO. Protein Science,15(1): 182- 189
  • 10Bornstein P, Balian G. Cleavage at Asn-Gly bonds with hydroxylamine. Meth Enzy-Mol, 1997, 47(Part E): 132- 145

共引文献851

同被引文献69

  • 1Nishimura T, Nakatake Y, Konishi M, et al. Identification of anovel FGF, FGF21, preferentially expressed in the liver. BiochimBiophys Acta, 2000,1492(1): 203-206.
  • 2Ogawa Y, Kurosu H, Yamamoto M, et al. Beta-Klotho is requiredfor metabolic activity of fibroblast growth factor 21. Proc Natl AcadSci USA, 2007,104(18): 7432-7437.
  • 3Mai K, Schwarz F, Bobbert T, et d. Relation between fibroblastgrowth factor-21, adiposity, metabolism and weight reduction.Metabolism, 2011,60(2): 306-311.
  • 4Wente W, Efanov A M,Brenner M,et al. Fibroblast growthfactor-21 improves pancreatic beta-cell function and survival byactivation of extracellular signal-regulated kinase 1/2 and Aktsignaling pathways. Diabetes, 2006,55(9): 2470-2478.
  • 5Kharitonenkov A, Wroblewski V J, Koester A, et al. The metabolicstate of diabetic monkeys is regulated by fibroblast growthfactor-21. Endocrinology, 2007,148(2): 774-781.
  • 6Coskun T, Bina H A, Schneider M A, et al. Fibroblast growth factor21 corrects obesity in mice. Endocrinology, 2008,149(12): 6018-6027.
  • 7Wang W F, Li D S, Li X K. A new insight into treatment of diabetesmellits - fibroblast growth factor 21. Chin Pharmacol Bull,2009,25(4): 433-435.
  • 8Kharitonenkov A, Shiyanova T L, Koester A, et al. FGF21 as anovel metabolic regulator. J Clin Invest, 2005,115(6): 1627-1635.
  • 9Goetz R, Beenken A, Ibrahimi O A, et al. Molecular insights intothe klotho-dependent, endocrine mode of action of fibroblastgrowth factor 19 subfamily members. Mol Cell Biol, 2007,27(9):3417-3428.
  • 10Micanovic R, Raches D W,Dunbar J D,et al. Different roles of N-and C- termini in the ftinctional activity of FGF21. J Cell Physiol,2009,219(2): 227-234.

引证文献6

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部